A Quote by Heather Bresch

The pricing of a pharmaceutical product is opaque and frustrating, especially for patients. — © Heather Bresch
The pricing of a pharmaceutical product is opaque and frustrating, especially for patients.
It [the pharmaceutical industry] is the most profitable industry in the world, and partially funds the US government. It surpasses oil in terms of profits and my country recently went to war due to oil pricing. What does that say they will do to keep this other industry in tact? It is up to patients and their families to question what they are being given, and to consumers to demand better, more natural alternatives.
President Trump has exposed the dirty secret of drug pricing: There is a shadowy third player in the transaction between patients and their pharmacists: middlemen who have taken a big kickback from the drug manufacturer, which may or may not be reflected in patients' out-of-pocket costs.
Derivatives serve practically no purpose except to enrich bankers through opaque pricing and to deceive investors through off-the-balance-sheet accounting.
Federal laws against kickbacks bar pharmaceutical companies from directly giving money to patients for co-payments on the drugs they make.
The doctor should be opaque to his patients and, like a mirror, should show them nothing but what is shown to him.
We are market based and have to differentiate our product in many ways; pricing isn't the only one.
Baker has done it again! Building on the core principles that he advanced in Professional's Guide to Value Pricing and The Firm of the Future, Ron Baker has again evolved thought leadership on the critical dynamics of value and pricing. Baker's latest work, Pricing on Purpose: Creating and Capturing Value, provides real-world examples and practical strategies that provide a framework for pricing optimization. His clarity of purpose and passionate call to action resonates in today's intellectual capital economy.
Marketing is the act of inventing the product. The effort of designing it. The craft of producing it. The art of pricing it. The technique of selling it.
Lets take away the incentives to do 'to' patients and instead create incentives to do 'for' patients, to be 'with' patients. We don't need to do comparative effectiveness trials to see if that works; we can just ask patients.
Things are opaque to us, and we are opaque to ourselves.
It was so frustrating to see ulcer patients having surgery, or even dying, when I knew a simple antibiotic treatment could fix the problem.
Micropayments are great if you use them for a product or service with certain properties. It must be one where you can get away with usage-based pricing, and where there is a strong rationale for making it cheap, yet not free.
We entered into the pharmaceutical industry in 1988, and since then, we have grown significantly on the back of a growing demand in India for pharmaceutical products.
Ford can't sell trucks currently, and GM is not selling as many cars as it would like to. That is a problem of product and pricing, not a systemic problem of abandonment by consumers.
I am a spiritual person. I'm a Catholic. I treat my patients, the dead patients, as live patients. I believe there is life after death. And I talk to my patients. I talk to them, not loudly but quietly in my heart when I look at them. Before I do an autopsy, I must have a visual contact with the face.
Whenever you see shrinks on television, they're so clearly written by patients. They're either idealized or they're demonized or they love their patients. All they ever think about is their patients.
This site uses cookies to ensure you get the best experience. More info...
Got it!